Search results
hATTR Amyloidosis Treatment: A Glimpse at Available and Future Options
Verywell Health via Yahoo News· 2 months agoPromising therapies aim to treat hATTR and improve quality of life Medically reviewed by Stella...
Amyloidosis Genetic Testing to Assess hATTR Risk
Verywell Health via Yahoo News· 2 months agoGenetic testing can unlock early treatment and may even be lifesaving Medically reviewed by Steffini Stalos, DO If one of your close biological relatives...
Hereditary Transthyretin (hATTR) Amyloidosis: Effect on Life Expectancy
Verywell Health via Yahoo News· 2 months agoHereditary transthyretin (hATTR) amyloidosis has a significant disease burden because of its affect...
What to Know About Amyloidosis
Verywell Health via Yahoo News· 9 months agoSymptoms, Causes, Diagnosis, and Treatment HengDao / Getty Images Medically reviewed by Jay N. Yepuri, MD, MS Amyloidosis is a rare disease in which...
Hereditary ATTR (hATTR) Amyloidosis Prognosis: What to Know
Verywell Health via Yahoo News· 2 months agoStatistics of hereditary ATTR (hATTR) amyloidosis reveal a poor prognosis. This is because of the...
Signs and Symptoms of hATTR Amyloidosis
Verywell Health via Yahoo News· 2 months agoHereditary transthyretin (hATTR) amyloidosis symptoms can affect various parts of the body and may not seem connected. They also vary from person to...
Role of Genes in hATTR Amyloidosis
Verywell Health via Yahoo News· 2 months agoAn inherited disease caused by abnormal protein buildup Medically reviewed by Kashif J. Piracha, MD Hereditary ATTR amyloidosis (hATTR amyloidosis) is a...
Understanding hATTR Amyloidosis With Polyneuropathy
Verywell Health via Yahoo News· 2 months agoThe condition hATTR amyloidosis causes polyneuropathy symptoms that impact different organ systems. Learn about nerve damage in hereditary amyloidosis.
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Zacks via Yahoo Finance· 1 month agoIntellia Therapeutics, Inc. NTLA announced that it has dosed the first patient in the phase III...
Could This Stock Be the Next Biotech Buyout?
Motley Fool· 9 months agoShares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this...